Literature DB >> 18444087

West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons.

John D Morrey1, Venkatraman Siddharthan, Hong Wang, Jeffery O Hall, Ramona T Skirpstunas, Aaron L Olsen, Jeffrey L Nordstrom, Scott Koenig, Syd Johnson, Michael S Diamond.   

Abstract

Acute flaccid polio-like paralysis occurs during natural West Nile virus (WNV) infection in a subset of cases in animals and humans. To evaluate the pathology and the possibility for therapeutic intervention, the authors developed a model of acute flaccid paralysis by injecting WNV directly into the sciatic nerve or spinal cord of hamsters. By directly injecting selected sites of the nervous system with WNV, the authors mapped the lesions responsible for hind limb paralysis to the lumbar spinal cord. Immunohistochemical analysis of spinal cord sections from paralyzed hamsters revealed that WNV-infected neurons localized primarily to the ventral motor horn of the gray matter, consistent with the polio-like clinical presentation. Neuronal apoptosis and diminished cell function were identified by TUNEL (terminal deoxynucleotidyl transferase-mediated BrdUTP nick end labeling) and choline acetyltransferase staining, respectively. Administration of hE16, a potently neutralizing humanized anti-WNV monoclonal antibody, 2 to 3 days after direct WNV infection of the spinal cord, significantly reduced paralysis and mortality. Additionally, a single injection of hE16 as late as 5 days after WNV inoculation of the sciatic nerve also prevented paralysis. Overall, these experiments establish that WNV-induced acute flaccid paralysis in hamsters is due to neuronal infection and injury in the lumbar spinal cord and that treatment with a therapeutic antibody prevents paralysis when administered after WNV infection of spinal cord neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444087      PMCID: PMC2583443          DOI: 10.1080/13550280801958930

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  30 in total

1.  Recovery and prognosticators of paralysis in West Nile virus infection.

Authors:  Nancy Jingyang Cao; Chakpapani Ranganathan; William J Kupsky; Jun Li
Journal:  J Neurol Sci       Date:  2005-09-15       Impact factor: 3.181

2.  Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Grant Y Roper; Hong Wang; Thomas J Baldwin; Scott Koenig; Syd Johnson; Jeffrey L Nordstrom; Michael S Diamond
Journal:  J Infect Dis       Date:  2006-09-22       Impact factor: 5.226

3.  Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.

Authors:  Melanie A Samuel; John D Morrey; Michael S Diamond
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

4.  Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein.

Authors:  Wonkyung Oh; Mi-Ran Yang; Eun-Woo Lee; Ki-Moon Park; Suhkneung Pyo; Joo-Sung Yang; Han-Woong Lee; Jaewhan Song
Journal:  J Biol Chem       Date:  2006-08-01       Impact factor: 5.157

5.  Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses.

Authors:  R S Lanciotti; A J Kerst
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival.

Authors:  Justin G Julander; Quinton A Winger; Aaron L Olsen; Craig W Day; Robert W Sidwell; John D Morrey
Journal:  Antiviral Res       Date:  2005-02       Impact factor: 5.970

7.  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Hong Wang; Justin G Julander; Jeffery O Hall; Hua Li; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

8.  Successful protection by amantadine hydrochloride against lethal encephalitis caused by a highly neurovirulent recombinant influenza A virus in mice.

Authors:  Isamu Mori; Beixing Liu; Md Jaber Hossain; Hiroki Takakuwa; Tohru Daikoku; Yukihiro Nishiyama; Hironobu Naiki; Kazuo Matsumoto; Takashi Yokochi; Yoshinobu Kimura
Journal:  Virology       Date:  2002-11-25       Impact factor: 3.616

9.  Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis.

Authors:  Melanie A Samuel; Hong Wang; Venkatraman Siddharthan; John D Morrey; Michael S Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-15       Impact factor: 11.205

10.  Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway.

Authors:  Joo-Sung Yang; Mathura P Ramanathan; Karuppiah Muthumani; Andrew Y Choo; Sung-Ha Jin; Qian-Chun Yu; Daniel S Hwang; Daniel K Choo; Mark D Lee; Kesen Dang; Waixing Tang; J Joseph Kim; David B Weiner
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more
  29 in total

1.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus.

Authors:  John H Beigel; Jeffrey L Nordstrom; Stanley R Pillemer; Cory Roncal; D Ronald Goldwater; Hua Li; P Chris Holland; Syd Johnson; Kathryn Stein; Scott Koenig
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

3.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

4.  Activation of innate immune responses in the central nervous system during reovirus myelitis.

Authors:  Stephanie A Schittone; Kalen R Dionne; Kenneth L Tyler; Penny Clarke
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.

Authors:  Jessica A Plante; Maricela Torres; Claire Y-H Huang; David W C Beasley
Journal:  Virology       Date:  2016-06-07       Impact factor: 3.616

Review 6.  Viral diseases of the central nervous system.

Authors:  Phillip A Swanson; Dorian B McGavern
Journal:  Curr Opin Virol       Date:  2015-02-12       Impact factor: 7.090

Review 7.  Neurological approaches for investigating West Nile virus disease and its treatment in rodents.

Authors:  John D Morrey; Venkatraman Siddharthan; Hong Wang
Journal:  Antiviral Res       Date:  2013-09-19       Impact factor: 5.970

8.  Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1.

Authors:  Cynthia A Smeraski; Venkatraman Siddharthan; John D Morrey
Journal:  Antiviral Res       Date:  2011-04-30       Impact factor: 5.970

Review 9.  Apoptosis in animal models of virus-induced disease.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

10.  Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation.

Authors:  Venkatraman Siddharthan; Hong Wang; Neil E Motter; Jeffery O Hall; Robert D Skinner; Ramona T Skirpstunas; John D Morrey
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.